Search Results
May 26, 2026, 09:33 ET Lupus Research Alliance and Genentech Fund Researchers Translating CAR T Success into Durable Lupus Treatments
shown remarkable success in oncology and is now being studied in people with severe lupus. In ongoing clinical trials, some lupus patients treated with CD19-targeted CAR-T cells who had not responded to standard treatments experienced rapid, deep remission, allowing them to stop all other lupus medications.
More news about: Lupus Research Alliance
May 26, 2026, 08:10 ET Menarini Group、American Society of Clinical Oncology (ASCO)の2026年年次総会で新データを発表
Groupの完全子会社であるStemline Therapeutics, Inc.（「Stemline」）は、コマーシャル・ステージにあるバイオ医薬品会社で、患者に革新的ながん治療を提供することに注力しています。Stemlineは、エストロゲン受容体（ER）陽性、ヒト上皮成長因子受容体2（HER2）陰性、ESR1遺伝子変異の進行・転移性乳がんで、少なくとも1ライン以上の内分泌療法後に病勢進行した閉経後女性または成人男性の治療を適応症とする経口内分泌療法剤エラセストラントを、米国、欧州をはじめとする世界各地で販売しています。また、Stemlineは、CD123に対する新規標的治療薬であるタグラクソフスプ・エルツを、ア
More news about: Menarini Industrie Farmaceutiche Riunite
May 26, 2026, 00:35 ET Over 40 Studies Featuring Akeso's Innovative Oncology Agents to Be Presented at ASCO 2026: Ivonescimab's HARMONi-6 Overall Survival Data Selected for Plenary Session
antibodies — cadonilimab (PD-1/CTLA-4) and ivonescimab (PD-1/VEGF) — along with other novel therapeutic antibodies such as ligufalimab, a next-generation CD47 monoclonal antibody. These presentations include several potentially practice-changing datasets across multiple tumor types.A pivotal highlight
More news about: Akeso, Inc.
May 25, 2026, 11:56 ET 메나리니 그룹, 2026 미국임상종양학회(ASCO) 연례회의에서 새로운 데이터 발표
2(HER2) 음성, ESR1 변이 진행성 또는 전이성 유방암을 앓는 폐경 후 여성 또는 성인 남성 치료에 적응증을 보유한 경구용 내분비 요법제다. 또한 스템라인은 미국, 유럽 및 기타 글로벌 지역에서 공격성 혈액암인 모구성 형질세포양 수지상세포 종양(BPDCN) 환자를 위한 CD123 표적 신규 표적치료제 타그락소푸스프-erzs를 상용화하고 있다. 이와 함께 스템라인은 유럽에서 다발골수종 치료용 XPO1 억제제 셀리넥서를 상용화하고 있다. 회사는 또한 유방암 및 혈액암 적응증에서 각각 엘라세스트란트와 타그락소푸스프의 다수 적응증 확대 연구를
More news about: Menarini Industrie Farmaceutiche Riunite
May 25, 2026, 09:47 ET Menarini anuncia nuevos datos en la reunión anual de la Sociedad Americana de Oncología Clínica (ASCO) 2026
terapia endocrina, en Estados Unidos, Europa y otras regiones del mundo. Stemline también comercializa tagraxofusp-erzs, una novedosa terapia dirigida a CD123, para pacientes con neoplasia blástica de células dendríticas plasmocitoides (BPDCN), un cáncer hematológico agresivo, en Estados Unidos, Europa y otras
More news about: Menarini Industrie Farmaceutiche Riunite
May 25, 2026, 08:13 ET Menarini Group gibt neue Daten auf der Jahrestagung 2026 der American Society of Clinical Oncology (ASCO) bekannt
endokriner Therapie in den USA, Europa und anderen globalen Regionen angezeigt ist. Stemline vermarktet auch Tagraxofusp-erzs, eine neuartige, gegen CD123 gerichtete Therapie für Patienten mit blastischen plasmazytoiden dendritischen Zellneoplasien (BPDCN), einer aggressiven hämatologischen Krebserkrankung,
More news about: Menarini Industrie Farmaceutiche Riunite
May 25, 2026, 08:06 ET Menarini Group annonce de nouvelles données lors de la réunion annuelle 2026 de l'American Society of Clinical Oncology (ASCO)
Stemline commercialise également aux États-Unis, en Europe et dans d'autres régions du monde le tagraxofusp-erzs, une nouvelle thérapie ciblée sur le CD123, pour les patients atteints de néoplasme blastique des cellules dendritiques plasmacytoïdes (BPDCN), un cancer hématologique agressif. En outre, Stemline
More news about: Menarini Industrie Farmaceutiche Riunite
May 25, 2026, 08:03 ET Menarini Group Anuncia Novos Dados na Reunião Anual da American Society of Clinical Oncology (ASCO) 2026
de terapia endócrina, nos EUA, Europa e outras regiões globais. A Stemline também comercializa o tagraxofusp-erzs, uma nova terapia direcionada ao CD123, para pacientes com neoplasia de células dendríticas plasmocitoides blásticas (BPDCN), um câncer hematológico agressivo, nos Estados Unidos, Europa
More news about: Menarini Industrie Farmaceutiche Riunite
May 25, 2026, 07:46 ET El Grupo Menarini anuncia nuevos datos en la Reunión Anual de la Sociedad Estadounidense de Oncología Clínica (asco) 2026
terapia endocrina, en EE. UU., Europa y otras regiones del mundo. Stemline además comercializa tagraxofusp-erzs, una novedosa terapia dirigida contra CD123, para pacientes con neoplasia blástica de células dendríticas plasmocitoides (BPDCN, por sus siglas en inglés), un cáncer hematológico agresivo, en
More news about: Menarini Industrie Farmaceutiche Riunite
May 25, 2026, 06:44 ET Menarini Group Announces New Data at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
endocrine therapy, in the U.S., Europe, and other global regions. Stemline also commercializes tagraxofusp-erzs, a novel targeted therapy directed to CD123, for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive hematologic cancer, in the United States, Europe, and other global
More news about: Menarini Industrie Farmaceutiche Riunite
May 22, 2026, 06:31 ET Simplilearn Partners with Virginia Tech to Launch A Certificate Program in Cloud Computing and DevOps
computing to the design of cloud architectures and the management of the DevOps lifecycle, on premise and on cloud. It covers key practices such as CI/CD pipelines, containerization with Docker, orchestration with Kubernetes, and infrastructure-as-code, while also introducing emerging areas like AIOps,
More news about: Simplilearn Solutions Private Limited
May 21, 2026, 22:40 ET 【2026 ASCO】亞盛醫藥公佈多項臨床進展，三項獲快速口頭報告
這是一項在SDH缺陷型腫瘤中的研究，評估了奧雷巴替尼在SDH缺陷型GIST和副神經節瘤患者中的療效。在26例SDH缺陷型GIST患者中，6例（23.1%）患者的最佳療效為PR，中位無進展生存期（PFS）長達25.7個月；在6例SDH缺陷型副神經節瘤患者中，4例患者觀察到最佳療效，SD持續≥4個周期（CBR，66.7%），中位PFS為8.25個月。該研究首次闡明了奧雷巴替尼通過p38-CD36通路抑制脂肪酸促進的腫瘤細胞遷移的新機制，為SDH缺陷型腫瘤的治療提供了全新思路。A phase 3 study of olverembatinib (HQP1351) in patients with chronic-phase chronic myeloid leukemia: POLARIS-2
More news about: 亞盛醫藥
May 21, 2026, 22:01 ET Lang Van Sues Hanoi's BH Media in U.S. Federal Court Over Alleged Piracy of 5,252 Vietnamese Sound Recordings
classification under U.S. trade law and the first PFC designation issued in 13 years. Vietnam's criminal action was launched under Prime Ministerial Telegram 38/CĐ-TTg, which initiated a nationwide intellectual property enforcement campaign following the USTR designation."For over forty years, Lang Van has
More news about: Lang Van, Inc.
May 21, 2026, 18:46 ET AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline
next-generation B-cell maturation antigen (BCMA) x CD3 T-cell engager, as monotherapy in a cohort of heavily pre-treated BCMA-exposed R/R MM patients will be presented at the meeting.Etentamig is an investigational BCMA and CD3 bispecific antibody T-cell engager composed of bivalent
More news about: AbbVie
May 21, 2026, 17:05 ET Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload
toward the clinic in the next 12-24 months."External Programs Validate CPT113 Linker-Payload Technology Hangzhou DAC's DXC006 is a CD56-directed ADC that utilizes CPT113. DXC006 is being evaluated in first-in-human Phase 1 dose escalation/expansion study in China (
More news about: Whitehawk Therapeutics, Inc.
May 21, 2026, 17:00 ET Boehringer Ingelheim's oncology portfolio shows strong promise across multiple cancers at ASCO 2026
(NSCLC) and early results evaluating HERNEXEOS in other types of cancer driven by HER2 alterations. Updated data for obrixtamig, an investigational DLL3/CD3-targeting T-cell engager, will also be presented in extensive-stage small cell lung cancer (ES-SCLC) and extrapulmonary neuroendocrine carcinoma (epNEC).
More news about: Boehringer Ingelheim
May 21, 2026, 16:05 ET Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China
vaccine developed for diseases associated with high-risk human papillomavirus (HPV) types 16 and 18. VGX-3100 is designed to elicit an antigen-specific, CD8+ T cell response to clear persistent HPV 16/18 infection, thereby promoting lesion regression and viral clearance.INOVIO licensed VGX-3100 to
More news about: INOVIO Pharmaceuticals, Inc.
May 21, 2026, 12:50 ET Samaritan's Purse responde al mortal brote de ébola en la República Democrática del Congo.
https://mma.prnewswire.com/media/2985564/1918CD_P2_133.jpgLogo -
More news about: Samaritan's Purse
May 21, 2026, 09:01 ET ATRA EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026
with Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD), who have received at least one prior therapy including an anti-CD20 containing regimen." Atara said that "[t]he CRL indicates that the FDA is unable to approve the EBVALLO™ BLA in its present form" because, according
More news about: Faruqi & Faruqi, LLP
May 21, 2026, 09:00 ET OneStream Launches AI-Assisted Developer Studio and Agentic Finance Toolkit
source control systems including Git, Azure DevOps, and SVNFlexible engineering workflows such as GitFlow, trunk-based development, and custom CI/CD pipelinesAgentic Finance Toolkit: Connecting AI Agents with Governed Finance Data and WorkflowsAlongside Developer Studio,
More news about: OneStream, Inc.
May 21, 2026, 07:00 ET BANKFIRST CAPITAL CORPORATION Announces Stock Repurchase Program
Alabama. BankFirst offers a wide variety of services for businesses and consumers. The Bank also offers internet banking, no-fee ATM access, checking, CD, and money market accounts, merchant services, mortgage loans, remote deposit capture, and more. For more information, visit
More news about: BankFirst Capital Corporation
May 21, 2026, 02:33 ET Gentoo Media publishes Q1 2026 interim report
https://mb.cision.com/Public/15972/4351268/a972824cd6dc5370.pdfGentoo Media Q1 2026
More news about: Gentoo Media Inc
May 21, 2026, 02:22 ET Gentoo Media publishes Q1 2026 interim report
https://mb.cision.com/Public/15972/4351268/a972824cd6dc5370.pdfGentoo Media Q1
More news about: Gentoo Media Inc
May 20, 2026, 08:00 ET Department of the Air Force and Istari Digital Unveil Industry Øne: The ARPANET for Engineering
demonstrate digital collaboration across toolsets, teams, and AI. Compliant by design."The program puts a new twist on repositories - the same CI/CD foundation that underpins modern software development - by adding the security and AI-auditability needed for national security missions.About
More news about: Istari Digital, Inc.
May 20, 2026, 08:00 ET Apica Grows Global SI Partner Network on the Strength of its Agentic-Ready, OpenTelemetry-Native Pipeline
area60–80% reduction in non-production storage costs through intelligent subsettingAutomated test data orchestration integrated directly into CI/CD pipelinesAgentic AI readiness: Agent-ready, API-enabled test data for IBM watsonx Orchestrate and other agentic platformsFull test
More news about: Apica